Chronic lymphocytic leukemia.
暂无分享,去创建一个
[1] A. Delannoy,et al. 2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL). , 1995, Leukemia.
[2] A Benner,et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.
[3] E. Raveche,et al. Growth inhibition of malignant CD5+B (B-1) cells by antisense IL-10 oligonucleotide. , 1995, Leukemia research.
[4] A. Saven,et al. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Angelopoulou,et al. Effective treatment of disease‐related anaemia in B‐chronic lymphocytic leukaemia patients with recombinant human erythropoietin , 1995, British journal of haematology.
[6] E. Montserrat,et al. Chronic lymphocytic leukemia: present status. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] S. Singhal,et al. Unusual infections following allogeneic bone marrow transplantation for chronic lymphocytic leukemia. , 1994, Bone marrow transplantation.
[8] D. Catovsky,et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. , 1994, Leukemia.
[9] E. Montserrat,et al. Recent progress in chronic lymphocytic leukemia. International Workshop on chronic Lymphocytic Leukemia. , 1994, Leukemia.
[10] F. Ries,et al. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes , 1994, British journal of haematology.
[11] C. Geisler,et al. Treatment of hypogammaglobulinemia in chronic lymphocytic leukaemia by low‐dose intravenous gammaglobulin , 1994, European journal of haematology.
[12] H. Tilly,et al. Residual disease in B-cell chronic lymphocytic leukemia patients and prognostic value. , 1994, Leukemia.
[13] G. Dighiero,et al. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. , 1994, Immunology today.
[14] G. Gaidano,et al. Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia. , 1994, The American journal of pathology.
[15] S. Molica. Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment. , 1994, Leukemia & lymphoma.
[16] B. Andersson,et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] R. Pirker,et al. MDR1 gene expression in chronic lymphocytic leukemia. , 1994, Leukemia & lymphoma.
[18] G. Inghirami,et al. Molecular genetic demonstration of the diverse evolution of Richter's syndrome (chronic lymphocytic leukemia and subsequent large cell lymphoma) , 1994 .
[19] G. Gahrton,et al. 5 Cytogenetics in CLL and related disorders , 1993 .
[20] E. Montserrat,et al. 6 Chronic lymphocytic leukaemia: Prognostic factors and natural history , 1993 .
[21] E. Newcomb,et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression , 1993 .
[22] H. Kantarjian,et al. Richter's syndrome: a report on 39 patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] K. Ganeshaguru,et al. Autocrine and paracrine growth loops in chronic lymphocytic leukemia. , 1993, Seminars in hematology.
[24] John Calvin Reed,et al. bcl-2 Gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia , 1993 .
[25] D. Neuberg,et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. , 1993, Blood.
[26] A. Berrebi,et al. Mechanism of autoimmune hemolytic anemia in chronic lymphocytic leukemia , 1993, American journal of hematology.
[27] D. Catovsky,et al. Trisomy 12 in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: analysis by stage, immunophenotype, and morphology. , 1993, Blood.
[28] L. Hawthorn,et al. The consistent 13q14 translocation breakpoint seen in chronic B-cell leukaemia (BCLL) involves deletion of the D13S25 locus which lies distal to the retinoblastoma predisposition gene. , 1993, Oncogene.
[29] E. Estey,et al. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. , 1993, Blood.
[30] A. Novarino,et al. The nature of the B lymphocyte in B-chronic lymphocytic leukemia. , 1993, Blood cells.
[31] E. Anaissie,et al. Listeriosis in Patients with Chronic Lymphocytic Leukemia Who Were Treated with Fludarabine and Prednisone , 1992, Annals of Internal Medicine.
[32] M. Tsan,et al. Cyclosporine and prednisone therapy for pure red cell aplasia in patients with chronic lymphocytic leukemia , 1992, American journal of hematology/oncology.
[33] H. Kantarjian,et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. , 1992, Blood.
[34] M. Linet,et al. Chronic leukaemias. , 1992, Bailliere's clinical haematology.
[35] E. Montserrat,et al. alpha Interferon in chronic lymphocytic leukaemia. , 1991, European journal of cancer.
[36] H Tesch,et al. Human chronic lymphocytic leukemia cells regularly express mRNAs of the protooncogenes lck and c-fgr. , 1991, Leukemia research.
[37] D. Catovsky,et al. CLL Trials in the United Kingdom the Medical Research Council CLL Trials 1, 2 and 3. , 1991, Leukemia & lymphoma.
[38] S. Rodenhuis,et al. Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer. , 1990, Journal of the National Cancer Institute.
[39] M. Raffeld,et al. Chromosomal translocation t(14;19) as indicated by bcl-3 rearrangement is a rare phenomenon in non-Hodgkin's lymphoma and chronic lymphocytic leukemia: a molecular genetic analysis of 176 cases. , 1990, Leukemia.
[40] B. Grosbois,et al. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. The French Cooperative Group on Chronic Lymphocytic Leukemia. , 1990, Blood.
[41] H. Gralnick,et al. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. , 1989, Journal of clinical pathology.
[42] M. Grever,et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the national cancer institute‐sponsored working group , 1988, American journal of hematology.
[43] A. Randomized. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. , 1988 .
[44] Ciril Rozman,et al. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance , 1986, British journal of haematology.
[45] E. Montserrat,et al. Bone marrow histologic pattern--the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. , 1984, Blood.
[46] E. Montserrat,et al. Prognosis of chronic lymphocytic leukemia: a multivariate survival analysis of 150 cases , 1982 .
[47] Mark J. Thomas,et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis , 1981, Cancer.
[48] D. Catovsky,et al. ‘Prolymphocytoid’ Transformation of Chronic Lymphocytic Leukaemia , 1979, British journal of haematology.
[49] E. Cronkite,et al. Clinical staging of chronic lymphocytic leukemia. , 1975, Blood.